Head to Head Analysis: enGene (ENGN) and Its Rivals

enGene (NASDAQ:ENGN) is one of 671 public companies in the “Holding & other investment offices” industry, but how does it weigh in compared to its competitors? We will compare enGene to similar businesses based on the strength of its valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and profitability.

Volatility and Risk

enGene has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, enGene’s competitors have a beta of 0.04, indicating that their average share price is 96% less volatile than the S&P 500.

Valuation and Earnings

This table compares enGene and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
enGene	N/A	$30,000.00	-5.52
enGene Competitors	$964.75 million	$74.29 million	46.88

enGene’s competitors have higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares enGene and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	N/A	-5.65%
enGene Competitors	-20.12%	-42.63%	-0.78%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for enGene and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	6	0	3.00
enGene Competitors	127	572	871	15	2.49

enGene currently has a consensus price target of $34.40, indicating a potential upside of 282.22%. As a group, “Holding & other investment offices” companies have a potential upside of 49.09%. Given enGene’s stronger consensus rating and higher possible upside, equities analysts clearly believe enGene is more favorable than its competitors.

Insider and Institutional Ownership

64.2% of enGene shares are held by institutional investors. Comparatively, 54.0% of shares of all “Holding & other investment offices” companies are held by institutional investors. 13.7% of enGene shares are held by company insiders. Comparatively, 25.9% of shares of all “Holding & other investment offices” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

enGene competitors beat enGene on 7 of the 13 factors compared.

enGene Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.